Press Release

April 23, 2025

‍Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies.

December 12, 2024

VERAXA Biotech and Navigo Proteins Initiate Research Collaboration to Establish Pre-Targeting Strategies for Novel Affilin Radio Conjugates

The agreement brings together Navigo Protein’s Affilin® platform with VERAXA’s proprietary click chemistry platform and conjugation expertise

July 18, 2024

VERAXA Biotech Launches New BiTAC Platform to Develop Breakthrough Antibody Therapies with Unprecedented Safety Features

BiTACs benefit from novel architecture with combinatorial-gated design for cancer targeting and built-in safety features